ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
COSCIENS Biopharma Inc

COSCIENS Biopharma Inc (CSCI)

4.00
-0.02
(-0.50%)
Closed December 08 4:12PM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
4.00
Bid
3.90
Ask
4.10
Volume
1,400
4.00 Day's Range 4.10
3.78 52 Week Range 9.00
Market Cap
Previous Close
4.02
Open
4.01
Last Trade
400
@
4
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
1,857
Shares Outstanding
4,856,000
Dividend Yield
-
PE Ratio
-1.17
Earnings Per Share (EPS)
-3.41
Revenue
4.5M
Net Profit
-16.55M

About COSCIENS Biopharma Inc

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Toronto, Ontario, Can
Founded
-
COSCIENS Biopharma Inc is listed in the Pharmaceutical Preparations sector of the Toronto Stock Exchange with ticker CSCI. The last closing price for COSCIENS Biopharma was $4.02. Over the last year, COSCIENS Biopharma shares have traded in a share price range of $ 3.78 to $ 9.00.

COSCIENS Biopharma currently has 4,856,000 shares outstanding. The market capitalization of COSCIENS Biopharma is $19.52 million. COSCIENS Biopharma has a price to earnings ratio (PE ratio) of -1.17.

CSCI Latest News

COSCIENS Biopharma Inc. Reports Third Quarter 2024 Financial Results and Provides Update on Advancements with Merger Integration Process and Ongoing Development Programs

Continued execution on merger integration with Ceapro Inc. and advancements across business Company ended the quarter with US$20.0 million in cash TORONTO, ONTARIO, Nov. 12, 2024 (GLOBE...

COSCIENS Biopharma Announces Change to Board of Directors

TORONTO, ONTARIO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a specialty biopharmaceutical company developing and...

COSCIENS Biopharma Announces Appointment of Pierre Labbé as Director

TORONTO, ONTARIO, Oct. 01, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a specialty biopharmaceutical company developing and...

COSCIENS Biopharma Inc. Provides Updates on Merger Integration, Management Succession Plans and Ongoing Development Programs

TORONTO, ONTARIO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a specialty biopharmaceutical company developing and...

COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

- Top-line data with unexpected results requiring further clarification, did not meet primary endpoint as per protocol - Potent growth hormone release following macimorelin stimulation - Safety of...

COSCIENS Biopharma Inc. Reports Second Quarter 2024 Financial Results

                Data from pivotal DETECT-Trial evaluating macimorelin for the diagnosis of childhood-onset growth hormone deficiency expected in Q3 2024 Company ended the quarter with US$27.8...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.15-3.614457831334.154.453.9923394.06076088CS
4-0.81-16.83991683994.814.813.7829194.17112308CS
12-1.65-29.2035398235.655.853.7818574.59818936CS
26-4.4-52.3809523818.493.7818665.04828309CS
52-4.4-52.3809523818.493.7818665.04828309CS
156-4.4-52.3809523818.493.7818665.04828309CS
260-4.4-52.3809523818.493.7818665.04828309CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
SMCSulliden Mining Capital Inc
$ 0.02
(33.33%)
5.05k
FLNTFlint Corporation
$ 0.025
(25.00%)
40.92k
CNTCentury Global Commodities Corporation
$ 0.03
(20.00%)
3k
APLIAppili Therapeutics Inc
$ 0.035
(16.67%)
401.3k
NCFNorthcliff Resources Ltd
$ 0.035
(16.67%)
1,000
CRWNCrown Capital Partners Inc
$ 1.40
(-24.73%)
4.61k
XTRAXtract One Technologies Inc
$ 0.53
(-19.70%)
352.94k
PPRPrairie Provident Resources Inc
$ 0.03
(-14.29%)
7.85k
PNPPinetree Capital Ltd
$ 11.88
(-13.35%)
55.5k
AVNTAvant Brands Inc
$ 0.53
(-13.11%)
12.55k
CNQCanadian Natural Resources Ltd
$ 45.65
(-2.12%)
19.21M
BITFBitfarms Ltd
$ 3.24
(9.83%)
11.15M
SUSuncor Energy Inc
$ 54.34
(-1.11%)
10.06M
TDToronto Dominion Bank
$ 73.53
(-0.66%)
9.31M
GWOGreat West Lifeco Inc
$ 48.76
(-0.23%)
7.15M

CSCI Discussion

View Posts
Patrickwan1 Patrickwan1 3 months ago
Completely lack of ability in doing clinical trials. Don’t trust these management!
👍️0
Patrickwan1 Patrickwan1 3 months ago
Damn it..bad management! A crab!
👍️0
at14tao at14tao 9 months ago
Great, now another reverse split coming. Now my .5 shares at $25,000/share will become .1 shares at $125,000/share.... lol but hey, I'll get .1 warrant to help cover my losses.... lol
👍️0
Awl416 Awl416 9 months ago
Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings
👍️0
ernie44 ernie44 10 months ago
Russian Sub runs aground in America

👍️0
ernie44 ernie44 1 year ago
ok this is my last one


👍️0
ernie44 ernie44 1 year ago
SHATNERS early days (ca. 1963 ) in show bizz




👍️0
ernie44 ernie44 1 year ago
AEZZZZZZZZZZZZZZZZZZZZZZZZZS SUCKS

👍️0
ernie44 ernie44 1 year ago
ZZZZZZZZZZZZZZZZZZZZZZ....................................................................................................................................................NO BODY SELLING EITHER......................................................................................






👍️0
ernie44 ernie44 1 year ago
or head north to escape the heat




👍️0
ernie44 ernie44 1 year ago
strike it rich like the Bev, Hillbullies

👍️0
ernie44 ernie44 1 year ago
MIGHT BE ON THIS LIST SOON

https://www.sec.gov/divisions/enforce/delinquent/delinqindex.htm
👍️0
ernie44 ernie44 1 year ago
think this one is done..... ?????
👍️0
ernie44 ernie44 2 years ago
were they trying to eliminate COVID -9.or what did Toronto think they are a foreign issuer...duhh
👍️0
livendi livendi 2 years ago
exactly,i have no idea what we were thinking,live and learn bro,God bless and good luck
👍️0
Patrickwan1 Patrickwan1 2 years ago
Nearly all management had been in this company for many many years.. seems dead wood already .. milking this company!
👍️0
Patrickwan1 Patrickwan1 2 years ago
This company has been listed for more than 30 years! But nothing achieved, really!
👍️0
livendi livendi 2 years ago
me too bro,God bless and good luck
👍️0
Patrickwan1 Patrickwan1 2 years ago
I should have known this is crab as there is No financial institution holding! This management has milk from shareholders for 30+ years !
👍️0
livendi livendi 2 years ago
sorry bro,put this pos behind u like i did,maybe it will jump a little on pedi approval but who knows how long that will take,only chance for this is other uses for macrilen but at the pace klauss and aezs goes that will take a decade,we should have known by aezs past,i was up 85k and ended up losing 15k so i feel your frustration,God bless and good luck
👍️0
Patrickwan1 Patrickwan1 2 years ago
Wtf, E&Y declined the reappointment as auditors !!
👍️0
ernie44 ernie44 2 years ago
they will try---- its not like a run on the stock.............


👍️0
Patrickwan1 Patrickwan1 2 years ago
Shorters are bastard earning nothing in shorting this kind of stock!!
👍️0
livendi livendi 2 years ago
what a f disaster,God bless and good luck
👍️0
Patrickwan1 Patrickwan1 2 years ago
Very bad… 99% holdings in hand of public!!!
👍️0
ernie44 ernie44 2 years ago
Confuscios say ''buy low---- sell high''






👍️0
Patrickwan1 Patrickwan1 2 years ago
Over 30 years company…Only 11 employees and very few financial institutional investors …very bad…
👍️0
livendi livendi 2 years ago
to boot klauss is making near 750k a yr for cratering aezs pps,sma aezs and klauss,God bless all
👍️0
livendi livendi 2 years ago
what a f disaster this has turned out to be,we all make mistakes and this is 1 for both of us,f aholes take forever to get things done,novo backed out of deal.this could easily go down below a buck again,sorry but we both fd up with this pos,tax rt off is all,and we all make mistakes sometimes,should have looked at past performance also,since its inception all it has done is go down,unless macrilen can be used for other things besides a test they got 0,sorry for our losses,God bless and good luck
👍️0
Patrickwan1 Patrickwan1 2 years ago
A crook..
👍️0
Patrickwan1 Patrickwan1 2 years ago
No more oral COVID pill… a spam..
👍️0
ernie44 ernie44 2 years ago
this stock seems to ALWAYS come back in SPADES
👍️0
ernie44 ernie44 2 years ago
a good friend of mine had 2 of those Citroens... a engineered marvel

👍️0
ernie44 ernie44 2 years ago
1950's were the days of the Jackal's

👍️0
Patrickwan1 Patrickwan1 2 years ago
Instead of giving updates, company chooses to publish those old information which already published .. it is not alert at all! It just so amazing a company keeps on publishing old information not bothering how public would expect.
👍️0
ernie44 ernie44 2 years ago
getting alerts every day now on AEZS
👍️0
ernie44 ernie44 2 years ago
on the list ???


Listing of Company Delinquent Filings Update
10/04/2022
You are subscribed to receive Listings of Company Delinquent Filings from the Securities and Exchange Commission.

This information has recently been updated and is now available.

https://www.sec.gov/divisions/enforce/delinquent/delinqindex.htm
👍️0
ernie44 ernie44 2 years ago
BOND JAMES couldnt save it,,, but James BLOND will ,,,,,with secret tricks


watch
👍️0
Elgordo84 Elgordo84 2 years ago


On November 16, 2020, the Company announced that it had entered into the Novo Amendment related to the development and commercialization of macimorelin. Novo is currently marketing macimorelin in the U.S. under the trade name Macrilen™ for the diagnosis of AGHD. Aeterna, in collaboration with Novo, is currently developing the expanded use of macimorelin for the diagnosis of CGHD, an area of significant unmet medical need.

On December 7, 2020, the Company entered into an exclusive licensing agreement with Consilient Health Limited (“CH” or “Consilient”) for the commercialization of macimorelin in the European Economic Area and the United Kingdom. In December 2021, the Department of Health and Social Care in the United Kingdom approved a list price which triggered a $226 (€0.2 million) pricing milestone payment from CH to the Company. In Germany, a list price was approved on June 15, 2022 which triggered a second $226 (€0.2 million) pricing milestone payment from CH to the Company. We shipped initial batches of macimorelin (Ghryvelin®) to Consilient in the first quarter of 2022. Consilient launched the product in the United Kingdom, Sweden and Denmark in May 2022 and launches in Germany and Finland are scheduled for July 2022.

We entered into license and supply agreements with NK Meditech Ltd. (“NK”), a subsidiary of PharmBio Korea, effective November 30, 2021, and a distribution and commercialization agreement with ER Kim Pharmaceuticals Bulgaria Food (“ER-Kim”), effective February 1, 2022. The agreements with NK are related to the development and commercialization of macimorelin for the diagnosis of AGHD and CGHD in the Republic of Korea, while the agreement with ER-Kim is related to the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults in Turkey and some non-European Union Balkan countries.

On April 19, 2022, we announced that European Patent Office had issued a patent providing intellectual property protection of macimorelin in 27 countries within the European Union as well as additional European non-EU countries, such as the UK and Turkey, for macimorelin (Ghryvelin®; Macrilen™) for use to diagnose GHD in adults.

Follow the money folks!!!

#ELGORDODAMUS
$AEZS
👍️0
Elgordo84 Elgordo84 2 years ago
Could this become a $100 ticker
In the next 6-18 months
It’s been on my radar for over a year
Let see how it plays out.

#ELGORDODAMUS
$AEZS
👍️0
ernie44 ernie44 2 years ago
yah, when you got a billion shares--there are lots of reverse splits to be done --- ..................................................................
👍️0
ernie44 ernie44 2 years ago
AEZS wants to be a BLUE chip outfit
👍️0
Patrickwan1 Patrickwan1 2 years ago
Further adjourning shareholders meeting. Klaus, don’t waste your time. It’s time to consider AEZS to buy back some share from the market. Or else AEZS is facing delisting..
👍️0
Patrickwan1 Patrickwan1 2 years ago
Really pk..
👍️0
Patrickwan1 Patrickwan1 2 years ago
Just a pump & dump.. really crab!
👍️0
Patrickwan1 Patrickwan1 2 years ago
Damn…
👍️0
livendi livendi 2 years ago
patrick i have to be honest,i sold because i needed the money to fix driveway,took a big hit but didnt have a choice really,God bless and good luck,sorry we were wrong about this 1 ,i dont know whats going to happen with this,if catalysts come to fruition it will jump back but at the rate they are going it could take a while and rs are almost always bad,God bless and good luck bro
👍️0
Patrickwan1 Patrickwan1 2 years ago
The share consolidation did not get shareholders approval… going to be delisted or going to pink… AEZS has sufficient cash to buy back 100 million shares and still leaving plenty amount for R&D. Buy back shares also show management is confident on its current candidates! AEZS is very risky facing delisted! What have you voted on this?
👍️0
livendi livendi 2 years ago
no way to test kids for ghd,no way,after approval it will help a lot,again no way to test kids for ghd,0 competition,what sucks is the delay because of putins war and the other catalysts takng forever like the covid pill,no urgency,sh feel it,check out tsoi,cant recommend per rules but check it out
👍️0
Patrickwan1 Patrickwan1 2 years ago
Shorters keep shorting this stock in view of RS. Management is bad and this stock is crab!
👍️0

Your Recent History

Delayed Upgrade Clock